EPCA-2: a highly specific serum marker for prostate cancer - Wikidata - wikimedia - TriplyDB

EPCA-2: a highly specific serum marker for prostate cancer

EPCA-2: a highly specific serum marker for prostate cancer

http://www.wikidata.org/entity/Q28298570

about

sameAs

False hopes, unwarranted fears: the trouble with medical news stories Serum early prostate cancer antigen (EPCA) level and its association with disease progression in prostate cancer in a Chinese population Nuclear structure as a source of cancer specific biomarkers.Best of the 2007 AUA Annual Meeting: Highlights from the 2007 Annual Meeting of the American Urological Association, May 19-24, 2007, Anaheim, CA.Promoter Methylation in Prostate Cancer and its Application for the Early Detection of Prostate Cancer Using Serum and Urine Samples.Cancer biomarkers: can we turn recent failures into success?Performance of a single assay for both type III and type VI TMPRSS2:ERG fusions in noninvasive prediction of prostate biopsy outcome.Progensa PCA3 test for prostate cancer detection.Prostate-specific antigen/solvent interaction analysis: a preliminary evaluation of a new assay concept for detecting prostate cancer using urinary samples.Analysis of a serum test for prostate cancer that detects a second epitope of EPCA-2.Genetic variants and family history predict prostate cancer similar to prostate-specific antigen Urinary Volatile Organic Compounds for the Detection of Prostate Cancer Blood biomarkers for prostate cancer detection and prognosis.New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer.The present and future of prostate cancer urine biomarkers.Evidence of heavy methylation in the galectin 3 promoter in early stages of prostate adenocarcinoma: development and validation of a methylated marker for early diagnosis of prostate cancer.Markers for detection of prostate cancer.Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer Biomarkers for prostate cancer detection.Immunotherapy of prostate cancer: should we be targeting stem cells and EMT?Formalized prediction of clinically significant prostate cancer: is it possible?Molecular biomarkers in prostate cancer.Beyond prostate-specific antigen: utilizing novel strategies to screen men for prostate cancer.Identification of specific nuclear structural protein alterations in human breast cancer.Translational bioinformatics for diagnostic and prognostic prediction of prostate cancer in the next-generation sequencing era.Prostate-specific antigen as a diagnostic tool: how useful and reliable is it?The role of free to total PSA ratio in prediction of extracapsular tumor extension and biochemical recurrence after radical prostatectomy in patients with PSA between 4 and 10 ng/ml.PSCA mRNA expression in preoperatively negative prostate biopsies predicts incidental prostate cancer in patients undergoing transurethral resection of the prostate for benign prostatic hyperplasia.Evaluation of D'Amico criteria for low-risk prostate cancer.New Prognostic Markers: The Pathway from Research to Clinical Practice

P2860

Q21563407-8A9E838D-4953-4672-819E-C7FEFC7CEF18 Q28478038-ABC31B57-F0AA-4022-906D-3BFF9851787A Q33282603-6E869F93-3618-4312-9B3B-22E99E2439F3 Q33302509-CD56AD05-86C9-47B9-9D7B-A463D35FE7E4 Q34014559-C70766B5-BAD4-4A31-B431-4C53F8D9DF64 Q34176379-619DEF65-7993-441D-A600-04628EEAF3B5 Q34296258-38373985-41FF-47B7-9307-24C006A434E9 Q34692442-BD2D4606-95D3-436B-9759-ED25C67D4078 Q35194458-FD2BA988-38FD-4D05-B9A3-02F229039AEB Q35228542-1C1B94B7-67F0-434F-976F-DA8017E01504 Q35277667-C5BE0F95-7011-4C54-9DCE-14CBAF046400 Q35849909-C1036623-CA19-47F2-9B96-0DEB9799F7C8 Q36895818-9A092648-2BEE-4FA7-B10A-F3FAAED06751 Q36973830-090B4165-950D-4D52-B9AC-6293E68FEBE4 Q37007392-A682EF4E-6966-45E8-943E-6E37DCE07BA9 Q37313689-38167DC3-1F0F-4E38-A2B6-3936EB4204D5 Q37328403-7697DA40-89ED-440A-9DCC-E6A77F1D8203 Q37422990-442F8C13-C30A-4001-8D82-63CFF9FEA118 Q37656233-EFA4A4D9-2188-4FDD-BA66-4C9DFE379D3B Q37891875-F27749AA-DB39-49C5-A92B-29ABC1B63944 Q37988363-C40FBC1D-2118-41C9-A303-DFA8984D3063 Q38088854-835ADCA0-1E1F-4510-B5D8-EFB021304EB9 Q38854599-5F56DB8F-3D71-46D2-B4BC-F8FE51801522 Q39512052-7A6044A9-ED65-4A82-A9D3-4043D0950CB0 Q42220108-C2547A1D-1BFA-4BC2-AE1F-4D931B289063 Q45022751-47D5056D-E0BA-42EF-AE50-9F81BEB5B604 Q45353776-B2529AC0-AA25-4415-B25B-4D5CA747630E Q46201624-09F1ECA8-83F8-4674-9445-0C6C44592323 Q50722577-BE865984-2709-409F-AA81-180E79399690 Q57238952-B7ECE7EE-0E0C-49EE-910A-112E69AE3A5F

P2860

EPCA-2: a highly specific serum marker for prostate cancer

http://www.wikidata.org/entity/Q28298570

description

2007 nî lūn-bûn

@nan

2007 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

EPCA-2: a highly specific serum marker for prostate cancer

@ast

EPCA-2: a highly specific serum marker for prostate cancer

@en

EPCA-2: a highly specific serum marker for prostate cancer

@nl

type

label

EPCA-2: a highly specific serum marker for prostate cancer

@ast

EPCA-2: a highly specific serum marker for prostate cancer

@en

EPCA-2: a highly specific serum marker for prostate cancer

@nl

altLabel

RETRACTED: EPCA-2: A Highly Specific Serum Marker for Prostate Cancer

@en

prefLabel

EPCA-2: a highly specific serum marker for prostate cancer

@ast

EPCA-2: a highly specific serum marker for prostate cancer

@en

EPCA-2: a highly specific serum marker for prostate cancer

@nl

P1433

Q28298570-D3B71E4B-66BC-4BB7-AEE2-590CDFB4A13E

P1476

Q28298570-15757868-D62D-4714-AC04-A1F3B1DAF702

Q28298570-ED95CCB6-82D0-4381-B680-2FD99A5FB40D

P2093

Q28298570-1C609B19-FCA1-4D05-AFB4-D7EEB72B4274

Q28298570-49DB164F-5135-4C0C-84B3-8EBC097514DE

Q28298570-6574A8AB-1238-4A99-A4FD-1E51BB43F23C

Q28298570-66B1A194-3EFD-4333-AB49-C0970FCC48EA

Q28298570-67691F7D-B19B-4CBF-B3FB-545D6761FC9E

Q28298570-7B11B5FB-B6C1-45BA-8BF2-A98ED9AFE69F

Q28298570-9E0EC2D8-637D-4E53-B7E9-B74451424DAC

Q28298570-A9E0209E-73F5-4975-8358-0163FE202380

Q28298570-BF02D41B-07EA-417B-BFF9-59FFB3D98564

Q28298570-D3BE0714-A91A-44F6-B27E-25E1F18654EC

P304

Q28298570-73A0CDB9-FCDD-467F-AC93-A509DA58517D

Q28298570-F76862B6-F681-476D-96C5-C82A88A79838

P31

Q28298570-9DD56DBC-8FD4-4693-B89C-DCADCA78F0E0

P356

Q28298570-FC7B64B3-31DB-42CF-B96F-4B317AEAE298

P407

Q28298570-85FA71C3-510F-4DC2-891E-3AB7195CEC89

P433

Q28298570-3106F1D5-7FF7-458A-A2D5-B66EAA283067

P478

Q28298570-0742BFA2-7F2B-49A8-9697-58CA5154F031

P50

Q28298570-67BA4668-5870-43CA-9932-E1EA6FAD14A6

P577

Q28298570-C359A7B9-91DC-44CE-BCEC-6E9697853A67

P5875

Q28298570-D0A1E33E-709D-43C2-BA73-90F631DFE4A6

P698

Q28298570-12840D8F-771E-4C31-9848-0D1CC7ABE862

P356

J.UROLOGY.2007.01.097

P1433

P1476

EPCA-2: a highly specific serum marker for prostate cancer

@en

RETRACTED: EPCA-2: A Highly Specific Serum Marker for Prostate Cancer

@en

P2093

Alan W. Partin

http://www.w3.org/2001/XMLSchema#string

Bruce J Trock

http://www.w3.org/2001/XMLSchema#string

Bruce J. Trock

http://www.w3.org/2001/XMLSchema#string

Daniel W Chan

http://www.w3.org/2001/XMLSchema#string

Daniel W. Chan

http://www.w3.org/2001/XMLSchema#string

Eddy S Leman

http://www.w3.org/2001/XMLSchema#string

Eddy S. Leman

http://www.w3.org/2001/XMLSchema#string

Grant W Cannon

http://www.w3.org/2001/XMLSchema#string

Grant W. Cannon

http://www.w3.org/2001/XMLSchema#string

Leslie Mangold

http://www.w3.org/2001/XMLSchema#string

P304

714-20

http://www.w3.org/2001/XMLSchema#string

714-720

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.UROLOGY.2007.01.097

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6382473

http://www.w3.org/2001/XMLSchema#string

P698

17445657

http://www.w3.org/2001/XMLSchema#string